The Effects of Cannabidiol and Homotaurine in Patients With Mild Cognitive Impairment
NCT ID: NCT05022186
Last Updated: 2021-08-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
90 participants
INTERVENTIONAL
2021-04-01
2022-12-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
CBD for Individuals at Risk for Alzheimer's Disease
NCT05822362
Use of a Product Containing the Cannabinoids CBD and THC as a Treatment Strategy for Alzheimer's Disease - Alzheimer's Disease and Cannabis Clinical Trial (DAZACANN) Open-Label Phase
NCT07091747
Use of a Cannabinoids as a Treatment Strategy for Alzheimer's Disease
NCT06570928
A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)
NCT05466422
Effects of THC-Free CBD Oil on Agitation in Patients With Alzheimer's Disease
NCT04436081
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group receiving Cannabidiol
These patients will receive cannabidiol 5% without other medication for cognition and depression
Cannabidiol Oil
Patients will use it with specific instructions and they will be monitored at least one time in a month
Group receiving Homotaurine
These patients will receive Vivimind (homotaurine) without other medication for memory and depression
Homotaurine
Patients will use it with specific instructions and they will be monitored at least one time in a month
Control group
These patients will not receive treatment
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cannabidiol Oil
Patients will use it with specific instructions and they will be monitored at least one time in a month
Homotaurine
Patients will use it with specific instructions and they will be monitored at least one time in a month
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Carry APOE ε4 gene
Exclusion Criteria
* Patients who receive medication for memory or depression
* Patients who do not carry APOE ε4 gene
65 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Greek Alzheimer's Association and Related Disorders
OTHER
Aristotle University Of Thessaloniki
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Magda Tsolaki
Professor of Neurology, Medical School, Aristotle University of Thessaloniki
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Greek Association of Alzheimer's Disease and Related Disorders
Thessaloniki, , Greece
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
65/06-02-2021
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.